{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:31:50Z","timestamp":1786555910626,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.leukres.2026.108272","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:21:37Z","timestamp":1783034497000},"page":"108272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bioluminescent xenograft model of acute myeloid leukemia for immunotherapy preclinical studies"],"prefix":"10.1016","volume":"168","author":[{"given":"Dina","family":"Senichkina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Pukhalskaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-3775","authenticated-orcid":false,"given":"Daria","family":"Bogdanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1542-4621","authenticated-orcid":false,"given":"Eugenia","family":"Platonova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Epifanovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Gaponenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Smirnova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Malashicheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5935-8973","authenticated-orcid":false,"given":"Andrey","family":"Russiyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Malakhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Musaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-9552","authenticated-orcid":false,"given":"Ekaterina","family":"Belozerkovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sukhorukova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukina","family":"Galina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Gusak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Baykov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3767-6840","authenticated-orcid":false,"given":"Alena","family":"Shakirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Lepik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4323-7174","authenticated-orcid":false,"given":"Oleg","family":"Demidov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.leukres.2026.108272_bib1","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2026.108272_bib2","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108272_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","article-title":"Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it","volume":"34","author":"Zeidan","year":"2019","journal-title":"Blood Rev."},{"issue":"26","key":"10.1016\/j.leukres.2026.108272_bib4","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"QUAZAR AML-001 Trial Investigators. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2026.108272_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.leukres.2026.108272_bib6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2026.108272_bib7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2026.108272_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101224","article-title":"CD33 directed bispecific antibodies in acute myeloid leukemia","volume":"33","author":"Clark","year":"2020","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.leukres.2026.108272_bib9","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1186\/s12967-024-05705-7","article-title":"Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia","volume":"22","author":"Zhao","year":"2024","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.leukres.2026.108272_bib10","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.bbmt.2019.03.011","article-title":"Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia","volume":"25","author":"Schroeder","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.leukres.2026.108272_bib11","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1186\/s12885-018-5020-3","article-title":"The 2018 Nobel Prize in medicine goes to cancer immunotherapy","volume":"18","author":"Guo","year":"2018","journal-title":"Editor. BMC Cancer). BMC Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2026.108272_bib12","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2026.108272_bib13","unstructured":"Gelead press release, as of 15 Feb 2024, available at \u3008https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/other\/magrolimab-trials-summary.pdf\u3009."},{"issue":"ement_1","key":"10.1016\/j.leukres.2026.108272_bib14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2019-129042","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2:2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"134","author":"Westervelt","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2026.108272_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275399","article-title":"Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis","volume":"17","author":"Moiseev","year":"2022","journal-title":"PLOS One"},{"issue":"3","key":"10.1016\/j.leukres.2026.108272_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.19","article-title":"A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia","volume":"5","author":"Saland","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2026.108272_bib17","doi-asserted-by":"crossref","unstructured":"E. Oswald, G. Greve, K. Klingner, B. Hammerich, D.Lenhard,\u00a0M. Pantic, M. Luebbert, D. Schueler, Paper: establishment and characterization of a panel of patient-derived acute leukemia mouse models as emerging platform for translational research. (2015). \u3008https:\/\/ash.confex.com\/ash\/2015\/webprogramscheduler\/Paper82821.html\u3009.","DOI":"10.1182\/blood.V126.23.2538.2538"},{"issue":"6","key":"10.1016\/j.leukres.2026.108272_bib18","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.3390\/ijms24065377","article-title":"Choosing the right cell line for acute myeloid leukemia (AML) research","volume":"24","author":"Skopek","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.leukres.2026.108272_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.17650\/1818-8346-2024-19-4-131-139","article-title":"Development of a preclinical model of myeloid tumors with high immune checkpoints expression","volume":"19","author":"Senichkina","year":"2024","journal-title":"Oncohematology"},{"issue":"3","key":"10.1016\/j.leukres.2026.108272_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1267\/ahc.19035","article-title":"Differential localization and invasion of tumor cells in mouse models of human and murine leukemias","volume":"53","author":"Mashima","year":"2020","journal-title":"Acta Histochem. Cytochem."},{"issue":"10","key":"10.1016\/j.leukres.2026.108272_bib21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.leukres.2005.03.019","article-title":"Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers","volume":"29","author":"Henschler","year":"2005","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.leukres.2026.108272_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/15384047.2019.1670520","article-title":"Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-\u03b3 to evaluate the efficacy of PD-L1\/PD-1-targeted immunotherapy","volume":"21","author":"Lin","year":"2020","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"10.1016\/j.leukres.2026.108272_bib23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.21320\/2500-2139-2021-14-4-414-425","article-title":"Acute myeloid leukemia patient-derived xenograft models generated with the use of immunodeficient NSG-SGM3 mice","volume":"14","author":"Baidyuk","year":"2021","journal-title":"Clin. Oncohematol."},{"issue":"1","key":"10.1016\/j.leukres.2026.108272_bib24","doi-asserted-by":"crossref","first-page":"9853","DOI":"10.1038\/s41467-024-54254-6","article-title":"Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2026.108272_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1195194","article-title":"Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy","volume":"14","author":"Lang","year":"2023","journal-title":"Front. Immunol."},{"issue":"24","key":"10.1016\/j.leukres.2026.108272_bib26","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1089\/scd.2016.0193","article-title":"Propagating humanized BLT mice for the study of human immunology and immunotherapy","volume":"25","author":"Smith","year":"2016","journal-title":"Stem Cells Dev."},{"issue":"1","key":"10.1016\/j.leukres.2026.108272_bib27","doi-asserted-by":"crossref","first-page":"9853","DOI":"10.1038\/s41467-024-54254-6","article-title":"Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.leukres.2026.108272_bib28","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1182\/blood-2012-10-464677","article-title":"AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model","volume":"121","author":"Wunderlich","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2026.108272_bib29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/sj.leu.2402882","article-title":"Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD\/SCID mice and in NOD\/SCID mice transgenic for human growth factors","volume":"17","author":"Feuring-Buske","year":"2003","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2026.108272_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209034","article-title":"Improved multilineage human hematopoietic reconstitution and function in NSGS mice","volume":"13","author":"Wunderlich","year":"2018","journal-title":"PLOS One"},{"issue":"11","key":"10.1016\/j.leukres.2026.108272_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116496","article-title":"A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potential","volume":"44","author":"Liu","year":"2025","journal-title":"Cell. Rep."},{"issue":"1","key":"10.1016\/j.leukres.2026.108272_bib32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1186\/s12885-019-5975-8","article-title":"Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2026.108272_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2026.129382","article-title":"The discovery of novel AKT inhibitor (4-(purin-6-yl)piperazin-1-yl)(benzofuran-2-yl)methanone for treatment of myeloid neoplasms: Computer modelling, synthesis and biological activity","volume":"449","author":"Semenov","year":"2026","journal-title":"J. Mol. Liq."},{"issue":"113","key":"10.1016\/j.leukres.2026.108272_bib34","doi-asserted-by":"crossref","DOI":"10.3791\/53609","article-title":"Bioluminescence-Based tumor quantification method for monitoring tumor progression and treatment effects in mouse lymphoma models","author":"Cosette","year":"2016","journal-title":"J. Vis. Exp."},{"issue":"5","key":"10.1016\/j.leukres.2026.108272_bib35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/acscentsci.2c00142","article-title":"Multiparameter longitudinal imaging of immune cell activity in chimeric antigen receptor T cell and checkpoint blockade therapies","volume":"8","author":"Xie","year":"2022","journal-title":"ACS Cent. Sci."},{"issue":"9","key":"10.1016\/j.leukres.2026.108272_bib36","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211986","article-title":"Insights into mechanisms of graft-versus-host disease through humanised mouse models","volume":"42","author":"Elhage","year":"2022","journal-title":"Biosci. Rep."},{"issue":"23","key":"10.1016\/j.leukres.2026.108272_bib37","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.4566","article-title":"Modelling graft-versus-host disease in mice using human peripheral blood mononuclear cells","volume":"12","author":"Haque","year":"2022","journal-title":"BIO-Protoc."},{"key":"10.1016\/j.leukres.2026.108272_bib38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3389\/fimmu.2019.00183","article-title":"GM-CSF promotes the expansion and differentiation of cord blood myeloid-derived suppressor cells, which attenuate xenogeneic graft-vs.-host disease","volume":"10","author":"Park","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.leukres.2026.108272_bib39","first-page":"4457","article-title":"Adoptive transfer of xenoantigen\u2011stimulated T cell receptor V\u03b2\u2011restricted human regulatory T cells prevents porcine islet xenograft rejection in humanized mice","volume":"18","author":"Jin","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"7","key":"10.1016\/j.leukres.2026.108272_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41568-021-00355-z","article-title":"Leukaemia: a model metastatic disease","volume":"21","author":"Whiteley","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2026.108272_bib41","doi-asserted-by":"crossref","first-page":"7305","DOI":"10.1038\/s41598-017-07848-8","article-title":"Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.leukres.2026.108272_bib42","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/bjh.19007","article-title":"Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response","volume":"203","author":"Apostolova","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108272_bib43","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1002\/ajh.27161","article-title":"Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes","volume":"99","author":"Brunner","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2026.108272_bib44","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1158\/0008-5472.CAN-12-1756","article-title":"Homing of human B cells to lymphoid organs and B-cell lymphoma engraftment are controlled by cell adhesion molecule JAM-C","volume":"73","author":"Do\u00f1ate","year":"2013","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.leukres.2026.108272_bib45","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2004-12-4969","article-title":"Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD\/SCID chimeric mice","volume":"106","author":"Tavor","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2026.108272_bib46","article-title":"A characterization of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors","author":"Gardam","year":"2025","journal-title":"bioRxiv"},{"issue":"4","key":"10.1016\/j.leukres.2026.108272_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100158","article-title":"Loss of STAT3 in acute myeloid leukemia favors tissue infiltration linked to CXCR4 signaling","volume":"2","author":"Zd\u00e1rsky","year":"2025","journal-title":"Blood Neoplasia"},{"issue":"3","key":"10.1016\/j.leukres.2026.108272_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100156","article-title":"An improved protocol for establishment of AML patient-derived xenograft models","volume":"1","author":"Hassan","year":"2020","journal-title":"STAR Protoc."},{"issue":"6","key":"10.1016\/j.leukres.2026.108272_bib49","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.3390\/ijms24065377","article-title":"Choosing the right cell line for acute myeloid leukemia (AML) research","volume":"24","author":"Skopek","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.leukres.2026.108272_bib50","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.leukres.2012.01.020","article-title":"Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro","volume":"36","author":"Madlambayan","year":"2012","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2026.108272_bib51","doi-asserted-by":"crossref","first-page":"674","DOI":"10.20517\/cdr.2023.39","article-title":"Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia","volume":"6","author":"Gurska","year":"2023","journal-title":"Cancer Drug. Resist."},{"issue":"1","key":"10.1016\/j.leukres.2026.108272_bib52","article-title":"Tumor immunotherapy: mechanisms and clinical applications","volume":"1","author":"Nong","year":"2022","journal-title":"MedComm Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212626001165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:37:06Z","timestamp":1786552626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212626001165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"alternative-id":["S0145212626001165"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108272","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioluminescent xenograft model of acute myeloid leukemia for immunotherapy preclinical studies","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2026.108272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108272"}}